$5370 | Single User
$5910 | Five User License
$7800 | Enterprise License

Global Intravenous Immunoglobulin Market (By Application, Types and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2014 - 2021
[Report Updated: 01-12-2016]

Published by Allied Market Research: 01 Dec 2016 | 103378 | In Stock
Related Topics: FDA , Healthcare

Introduction

IVIG is a sterile solution of antibodies collected from healthy donors, which is administered through the veins into the body. Currently, the immunoglobulin industry is growing on account of increasing FDA/EMA approvals and government support. IVIG usage against the conditions within the criteria (i.e. FDA/EMA approved indications) have increased greatly and the largest increase found in Chronic Inflammatory demyelinating polyneuropathy (CIDP), Hypogammaglobulinemia and immunodeficiency diseases. In addition, there has been a substantial increase in IVIG prescriptions for the treatment of off-label indications, such as, specific antibody deficiency, Guillain-Barre syndrome, Inflammatory Myopathies and others. However, factors such as the high cost of IVIG treatment, side effects associated with use of IVIG, stringent government regulations and a lengthy product approval process would hamper its market growth. Despite several challenges such as inadequate supply of immunoglobulins, stringent regulatory policies and the high cost associated with IVIG treatments, the global IVIG market would witness notable growth during the forecast period. nnGlobal IVIG market is segmented based on its types, application and geography. The application segment includes Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency diseases, Congenital AIDS, Chronic Lymphocytic Leukaemia (CLL), Myasthenia Gravis, Multifocal motor neuropathy, Idiopathic thrombocytopenic purpura (ITP), Kawasaki disease, Guillain-Barre syndrome, and others. Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP) holds a dominant share in the market due to a large patient population and the unavailability of effective alternatives for IVIG treatment. Geographically, the report covers five key regions, North America, Europe, Asia Pacific, and LAMEA. Presently, North America occupies a majority of the market followed by the Asia Pacific region. High adoption of IVIG therapies and a large pool of patient population in the North American region is a prime factor responsible for the growth of the North America IVIG market. However, in the Asia-pacific region, growing awareness for immunodeficiency disease & neurological disorders along with the increasing preference towards IVIG therapies, largely drives the market. The companies profiled in this report include Baxter international Inc., CSL Limited, Grifols S.A, Octapharma Ag, Kedrion Pharma, LFB group, Biotest AG, china Biologics products Ltd, Bayer Healthcare, and others. nnKEY  BENEFITSnnnnA comprehensive analysis of factors that drive and restrict the growth of the Global IVIG market. For instance, a large patient population and favorable government regulations will drive the Global IVIG market; however, the high cost of IVIG treatment and the associated risk of infection is likely to be a major restraint for the market.nnThe projections in the report are made by analyzing the current market trends and market potential for the period of 2014–2021, in terms of volume and valuennThe report covers a comprehensive analysis of all the geographic regions that help in determining the prevailing opportunities in these geographies. Government regulations regarding IVIG production and purification are discussed in detailnnCompetitive intelligence (of leading manufacturers of IVIG) helps in understanding the market scenario across geographiesnnSWOT analysis of the key market players is provided to illustrate the business strategies adopted by the companiesnnThe report provides a quantitative analysis of the current market and estimations through 2014-2021 that help in identifying the prevailing market opportunities.nnnKEY MARKET SEGMENT:nGlobal IVIG market is segmented based on the application, types and geographynnMARKET BY APPLICATIONnnnnHypogammaglobulinemia nnChronic Inflammatory demyelinating polyneuropathy (CIDP)nnImmunodeficiency diseasesnnCongenital AIDSnnChronic Lymphocytic Leukaemia (CLL)nnMyasthenia GravisnnMultifocal motor neuropathynnIdiopathic thrombocytopenic purpura (ITP)nnKawasaki diseasennGuillain-Barre syndrome nnOthersnn
 MARKET BY TYPEnnnnIgGnnIgAnnIgMnnIgEnnIgDnnnMARKET BY GEOGRAPHYnnnnNorth AmericannnnnnUnited StatesnnnCanadannnMexiconnnnnnEurope nnnnnGermanynnnFrancennnUnited KingdomnnnRussiannnAustriannnItaly nnnOthersnnnnnnAsia-Pacific nnnnnIndiannnChinannnJapannnnAustraliannnOthersnnnnnnLAMEAnnnnnLatin AmericannnMiddle EastnnnAfricannnnn

Table of Contents
for Global Intravenous Immunoglobulin Market (By Application, Types and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2014 - 2021 [Report Updated: 01-12-2016]

  • TABLE OF CONTENTS

    CHAPTER 1 INTRODUCTION

    1.1 Report description
    1.2 Key benefits
    1.3 Key market segment
    1.4 Research methodology

    1.4.1 Secondary Research
    1.4.2 Primary Research
    1.4.3 Analyst tools and models

    CHAPTER 2 EXECUTIVE SUMMARY

    2.1 CXO perspective
    2.2 Market beyond what to expect by 2026 ($Million)

    2.2.1 Moderate growth scenario
    2.2.2 Rapid growth scenario
    2.2.3 Diminishing growth scenario

    CHAPTER 3 MARKET OVERVIEW

    3.1 Market definition and scope
    3.2 Overview of Intravenous Immunoglobulin (IVIG)

    3.2.1 Patented products

    3.3 Epidemiology and economic burden of chronic conditions
    3.4 Cost of side effects due to IVIG treatments
    3.5 Key findings

    3.5.1 Top Factors Impacting global intravenous immunoglobulin market
    3.5.2 Top Investment pockets – Global Intravenous Immunoglobulin Market

    3.6 Porter’s five forces analysis

    3.6.1 Bargaining power of buyers (Low)
    3.6.2 Bargaining power of suppliers (Low)
    3.6.3 Threat of new entrants (low)
    3.6.4 Threat of substitutes (low)
    3.6.5 Intense competitive rivalry (moderate)

    3.7 Value chain analysis

    3.7.1 Primary activities
    3.7.2 Support Activities

    3.8 Market share analysis (2014)
    3.9 Product scenario in IVIG market
    3.10 Government regulations and reimbursements

    3.10.1 Intravenous Immunoglobulin (IVIG) regulations in United States and Europe
    3.10.2 Reimbursements Scenario

    3.11 Indications for IVIG

    3.11.1 USFDA Indications
    3.11.2 European Medicine Agency

    3.12 Component analysis of intravenous immunoglobulins (IgG)

    3.12.1 IgG1
    3.12.2 IgG2
    3.12.3 IgG3
    3.12.4 IgG4

    3.13 Clinical trials
    3.14 Patent analysis of IVIG market (2011-2014)

    3.14.1 Patent analysis by geography
    3.14.2 U.S. patent analysis
    3.14.3 Europe Patent Analysis

    3.15 Market dynamics

    3.15.1 Drivers

    3.15.1.1 Rising Number of immunodeficieny Deficiency
    3.15.1.2 Increase in adoption ofIVIG
    3.15.1.3 Increasing Number of People with Bleeding Disorders
    3.15.1.4 Rising Ageing Population

    3.15.2 Restraints

    3.15.2.1 Stringent Regulations
    3.15.2.2 High Cost of Therapy

    3.15.3 Opportunities

    3.15.3.1 Opportunities in emerging economies
    3.15.3.2 Development of cost effective therapeutics through large scale production

    CHAPTER 4 GLOBAL IVIG MARKET, BY APPLICATION, 2014-2021

    4.1 Hypogammaglobulinemia
    4.2 Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    4.1 Immunodeficiency diseases
    4.2 Congenital AIDS
    4.3 Chronic Lymphocytic Leukemia
    4.4 Myasthenia Gravis
    4.5 Multifocal motor neuropathy
    4.6 Primary Immune thrombocytopenia (ITP)
    4.7 Kawasaki disease
    4.8 Guillain-Barre syndrome
    4.9 Others

    CHAPTER 5 GLOBAL INTRAVENOUS IMMUNOGLOBULIN (IVIG) MARKET BY PRODUCT TYPES

    5.1 IgG

    5.1.1 Key Market Trends
    5.1.2 Clinical Interpretations

    5.2 IgA

    5.2.1 Key Market Trends
    5.2.2 Clinical interpretation

    5.3 IgM

    5.3.1 Key Market Trends
    5.3.2 Clinical Interpretation

    5.4 IgE

    5.4.1 Key Market Trends
    5.4.2 Clinical Interpretation

    5.5 IgD

    5.5.1 Key Market Trends

    CHAPTER 6 GLOBAL IVIG MARKET, BY GEOGRAPHY, 2014-2021

    6.1.1 Market size and forecast

    6.2 North America

    6.2.1 U.S.

    6.2.1.1 Key Market Trends
    6.2.1.2 Market size and forecast

    6.2.2 Canada

    6.2.2.1 Key Market Trends
    6.2.2.2 Market size and forecast
    6.2.2.3 Mexico
    6.2.2.4 Key Market Trends
    6.2.2.5 Market Size and forecast

    6.3 Europe

    6.3.1 Key market trends
    6.3.2 Market size and forecast
    6.3.3 U.K.

    6.3.3.1 Key Market Trend
    6.3.3.2 Market size and forecast

    6.3.4 France

    6.3.4.1 Key market trends
    6.3.4.2 Market size and forecast

    6.3.5 Germany

    6.3.5.1 Market size and forecast

    6.3.6 Italy

    6.3.6.1 Market size and forecast

    6.3.7 Austria

    6.3.7.1 market size and forecast

    6.3.8 Russia

    6.3.8.1 market size and forecast

    6.4 Asia-Pacific

    6.4.1 Key market trends
    6.4.2 Market size and forecast
    6.4.3 Australia

    6.4.3.1 Market size and forecast

    6.4.4 Japan

    6.4.4.1 Market size and forecast

    6.4.5 India

    6.4.5.1 Market size and forecast

    6.4.6 China

    6.4.6.1 Market size and forecast

    6.4.7 Others

    6.4.7.1 Market size and forecast

    6.5 LAMEA

    6.5.1 Key Market Trends
    6.5.2 Market size and forecast
    6.5.3 Latin America

    6.5.3.1 Market size and forecast

    6.5.4 Middle East

    6.5.4.1 Market size and forecast

    6.5.5 Africa

    6.5.5.1 Market size and forecast

    CHAPTER 7 COMPANY PROFILES

    7.1 Biotest AG

    7.1.1 Company overview
    7.1.2 Biotest AG snapshot
    7.1.3 Operating business segment overview
    7.1.4 Financial performance
    7.1.5 Strategic moves and developments
    7.1.6 SWOT analysis of Biotest AG

    7.2 Octapharma AG

    7.2.1 Company overview
    7.2.2 Octapharma AG snapshot
    7.2.3 Operating business segment overview
    7.2.4 Strategic moves and developments
    7.2.5 SWOT analysis of Octapharma AG

    7.3 Baxter International Inc.

    7.3.1 Company overview
    7.3.2 Baxter International Inc. snapshot
    7.3.3 Operating business segments overview
    7.3.4 Financial performance
    7.3.5 Strategic moves and developments
    7.3.6 SWOT analysis of Baxter International Inc.

    7.4 LFB Biotechnologies

    7.4.1 Company overview
    7.4.2 LFB Biotechnologies snapshot
    7.4.3 Operating business segment overview
    7.4.4 Financial performance
    7.4.5 SWOT analysis of LFB biotechnologies

    7.5 China Biologics Products Inc.

    7.5.1 Company overview
    7.5.2 China Biologic Products Inc. Snapshot
    7.5.3 Operating business segment overview
    7.5.4 Financial performance
    7.5.5 Strategic moves and developments
    7.5.6 SWOT analysis of China Biologic Products Inc.

    7.6 Grifols S.A.

    7.6.1 Company overview
    7.6.2 Grifols S.A Snapshot
    7.6.3 Operating Business Segment Overview
    7.6.4 Financial performance
    7.6.5 Strategic moves and developments
    7.6.6 SWOT analysis Grifols S.A.

    7.7 Kedrion Biopharma

    7.7.1 Company overview
    7.7.2 Kedrion Biopharma. Snapshot
    7.7.3 Operating business segment overview
    7.7.4 Financial performance
    7.7.5 Strategic moves and developments
    7.7.6 SWOT Analysis of Kedrion Biopharma.

    7.8 CSL Behring

    7.8.1 Company overview
    7.8.2 CSL Behring Snapshot
    7.8.3 Operating business segment overview
    7.8.4 Financial performance
    7.8.5 Strategic moves and developments
    7.8.6 SWOT ANALYSIS of CSL Behring

    7.9 BDI Pharma Inc.

    7.9.1 Company overview
    7.9.2 BDI pharma Inc. Snapshot
    7.9.3 Operating business segment overview
    7.9.4 SWOT Analysis of BDI Pharma

    7.10 Bayer Healthcare

    7.10.1 Company overview
    7.10.2 Business performance
    7.10.3 Strategic moves and developments
    7.10.4 SWOT analysis of Bayer Healthcare

    LIST OF TABLES

    TABLE 1  MODERATE GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 – 2026, ($MILLION)
    TABLE 2  MODERATE GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 – 2026, (TONNE)
    TABLE 3  RAPID GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 – 2026, ($MILLION)
    TABLE 4  RAPID GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 – 2026, (TONNE)
    TABLE 5  DIMINISHING GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 – 2026, ($MILLION)
    TABLE 6  DIMINISHING GROWTH SCENARIO OF IVIG MARKET BY GEOGRAPHY, 2021 – 2026, (TONNE)
    TABLE 7  IVIG PRODUCTS COMMERCIALIZED IN MARKET
    TABLE 8  USFDA INDICATIONS FOR IVIG
    TABLE 9  EMA APPROVED INDICATIONS FOR IVIG
    TABLE 10  IGG SUBCLASS
    TABLE 11  FREQUENCY (%) OF DECREASED IGG SUBCLASS CONCENTRATION IN ADULTS
    TABLE 12  DISEASE ASSOCIATE WITH IGG SUBCLASS DEFICIENCY
    TABLE 13  CLINICAL TRIALS FOR INTRAVENOUS IMMUNOGLOBULIN (2011-2014)
    TABLE 14  PATENT ANALYSIS- UNITED STATES (2010-2014)
    TABLE 15  PATENT ANALYSIS- EUROPE (2010-2014)
    TABLE 16  WORLD AGING POPULATION 2013
    TABLE 17  GLOBAL IVIG MARKET, BY APPLICATION, 2014–2021, $MILLION
    TABLE 18  GLOBAL IVIG MARKET, BY APPLICATION, 2014–2021, (TONNE)
    TABLE 19  COMMON MEDICATION FOR THE HYPOGAMMAGLOBULINEMIA ASSOCIATED WITH RECURRENT BACTERIAL INFECTIONS
    TABLE 20  HYPOGAMMAGLOBULINEMIA IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
    TABLE 21  CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP) IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
    TABLE 22  PRINCIPLE OF IVIG THERAPY IN IMMUNODEFICIENCY
    TABLE 23  IMMUNODEFICIENCY DISEASES IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
    TABLE 24  IVIG PRODUCTS FOR CONGENITAL AIDS
    TABLE 25  CONGENITAL AIDS IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
    TABLE 26  CLL STATISTICS 2011-2014
    TABLE 27  CHRONIC LYMPHOCYTIC LEUKAEMIA IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
    TABLE 28  MYASTHENIA GRAVIS IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
    TABLE 29  MULTIFOCAL MOTOR NEUROPATHY IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
    TABLE 30  ITP TREATMENT OPTIONS
    TABLE 31  ITP IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
    TABLE 32  KAWASAKI DISEASE PATIENTS PER 100,000 CHILDREN IN 2010
    TABLE 33  KAWASAKI DISEASE IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
    TABLE 34  GUILLAIN-BARRE SYNDROME IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
    TABLE 35  OTHER IVIG APPLICATION MARKET ($MILLION & TONNE), 2014-2021
    TABLE 36  GLOBAL IVIG MARKET BY GEOGRAPHY, 2014-2021, ($MILLION)
    TABLE 37  GLOBAL IVIG MARKET BY GEOGRAPHY, 2014-2021, (TONNE)
    TABLE 38  NORTH AMERICA IVIG MARKET, BY COUNTRY, 2014-2021, ($ MILLION)
    TABLE 39  NORTH AMERICA IVIG MARKET, BY COUNTRY, 2014-2021, (TONNE)
    TABLE 40  EUROPE IVIG MARKET, BY COUNTRY, 2014-2021, ($ MILLION)
    TABLE 41  EUROPE IVIG MARKET, BY COUNTRY, 2014-2021, (TONNE)
    TABLE 42  HIGH PRIORITY INDICATIONS OF IVIG
    TABLE 43  COST OF IVIG PRODUCTS IN UK
    TABLE 44  PRODUCTS CONTAINING IVIG IN ITALIAN MARKET
    TABLE 45  ASIA-PACIFIC IVIG MARKET, BY COUNTRY, 2014-2021, ($MILLION)
    TABLE 46  ASIA-PACIFIC IVIG MARKET, BY COUNTRY, 2014-2021, (TONNE)
    TABLE 47  IMMUNOGLOBULIN BRANDS AND ITS MANUFACTURERS
    TABLE 48  LAMEA IVIG MARKET, BY COUNTRY, 2014-2021, ($ MILLION)
    TABLE 49  LAMEA IVIG MARKET, BY COUNTRY, 2014-2021, (TONNE)
    TABLE 50  BIOTEST AG SANPSHOT
    TABLE 51  OPERATING BUSINESS SEGMENT OVERVIEW
    TABLE 52  OCTAPHARMA AG SNAPSHOT
    TABLE 53  OCTAPHARMA AG OPERATING BUSNIESS OVERVIEW
    TABLE 54  BAXTER INTERNATIONAL INC. SNAPSHOT
    TABLE 55  OPERATING BUSINESS SEGMENTS OVERVIEW
    TABLE 56  LFB BIOTECHNOLOGIES OPERATING SEGMENT OVERVIEW
    TABLE 57  CHINA BIOLOGIC PRODUCTS INC. SNAPSHOT
    TABLE 58  CHINA BIOLOGIC PRODUCTS INC. OPERATING BUSINESS SEGMENT OVERVIEW
    TABLE 59  GRIFOLS S.A SNAPSHOT
    TABLE 60  GRIFOLS S.A OPERATING SEGEMENTS
    TABLE 61  KEDRION INC. SNAPSHOT
    TABLE 62  KEDRION BIOPHARMA OPERATING SEGMENTS
    TABLE 63  CSL BEHRING SNAPSHOT
    TABLE 64  CSL BEHRING OPERATING SEGMENTS
    TABLE 65  BDI PHARMA INC SNAPSHOT
    TABLE 66  BDI PHARMA OPERATING SEGMENTS
    TABLE 67  BAYER HEALTHCARE COMPANY SNAPSHOT

    LIST OF FIGURES

    FIG. 1  IMPACT ANALYSIS OF GLOBAL IVIG MARKET IN MODERATE GROWTH SCENARIO
    FIG. 2  IMPACT ANALYSIS OF GLOBAL IVIG MARKET IN RAPID GROWTH SCENARIO
    FIG. 3  IMPACT ANALYSIS OF GLOBAL IVIG MARKET IN DIMINISHING GROWTH SCENARIO
    FIG. 4  PERCENTAGE SHARE OF COST ASSOCIATED WITH SIDE EFFECTS INDUCED BY IVIG THERAPY
    FIG. 5  TOP FACTORS IMPACTING GLOBAL IVIG MARKET (2015–2021)
    FIG. 6  TOP INVESTMENT POCKETS – GLOBAL INTRAVENOUS IMMUNOGLOBULIN MARKET
    FIG. 7  PORTER’S FIVE FORCES ANALYSIS
    FIG. 8  VALUE CHAIN ANALYSIS OF GLOBAL IVIG MARKET
    FIG. 9  MARKET SHARE ANALYSIS – GLOBAL IVIG MARKET 2014
    FIG. 10  PATENT ANALYSIS BY GEOGRAPHY (2011-2014)
    FIG. 11  U.S. PATENT ANALYSIS BY COMAPANY (2011–2014)
    FIG. 12  EUROPE PATENT ANALYSIS, BY COMPANY (2011–2014)
    FIG. 13  INCIDENCES OF HAEMOPHILIA, 2010
    FIG. 14  BIOTEST AG FINANCIAL PERFORMANCE BY PRODUCT SEGMENTS (2013)
    FIG. 15  BIOTEST AG FINANCIAL PERFORMANCE BY GEOGRAPHY (2013)
    FIG. 16  SWOT ANALYSIS OF BIOTEST AG
    FIG. 17  SWOT ANALYSIS OF OCTAPHARMA AG
    FIG. 18  BAXTER INTERNATIONAL INC. FINANCIAL PERFORMANCE BY PRODUCT SEGMENTS (2013)
    FIG. 19  BAXTER INTERNATIONAL INC. FINANCIAL PERFORMANCE BY GEOGRAPHY (2013)
    FIG. 20  SWOT ANALYSIS OF BAXTER INTERNATIONAL INC
    FIG. 21  L FB BIOTECHNOLOGIES FINANCIAL PERFORMANCE BY PRODUCT SEGMENT (2013)
    FIG. 22  LFB BIOTECHNOLOGIES FINANTIAL PERFORMANCE BY GEOGRAPHY (2013)
    FIG. 23  SWOT ANALYSIS OF LFB BIOTECHNOLOGIES
    FIG. 24  CHINA BIOLOGIC PRODUCTS INC. FINANCIAL PERFORMANCE BY SEGMENTS
    FIG. 25  SWOT ANALYSIS OF CHINA BIOLOGIC PRODUCTS INC.
    FIG. 26  FINANCIAL OF GRIFOLS S.A BY GEOGRAPHY (2013)
    FIG. 27  FINANCIAL GRIFOLS S.A. BY PRODUCT GROUPS (2013)
    FIG. 28  SWOT ANALYSIS OF GRIFOLS S.A.
    FIG. 29  FINANCIAL REVENUE OF KEDRION BIOPHARMA GEOGRAPHY (2013)
    FIG. 30  FINANCIAL KEDRION BIOPHARMA. BY PRODUCT GROUPS (2013)
    FIG. 31  SWOT ANALYSIS OF KEDRION BIOPHARMA
    FIG. 32  CSL BEHRING FINANCIAL REVENUE OF BY GEOGRAPHY (2013)
    FIG. 33  CSL BEHRING FINANCIAL REVENUE OF BY BUSINESS GROUP (2013)
    FIG. 34  SWOT ANALYSIS OF CSL BEHRING
    FIG. 35  SWOT ANALYSIS OF BDI PHARMA
    FIG. 36  FINANCIAL REVENUE OF BAYER HEALTHCARE (2013 AND 2012)
    FIG. 37  FINANCIALS OF BAYER HEALTHCARE, BY SEGMENTS, 2013
    FIG. 38  SWOT ANALYSIS OF BAYER HEALTHCARE 

Additional Details

Publisher

Allied Market Research

Publisher Information

Reference

103378 | LI 16325

Number of Pages

131

Report Format

PDF

Allied Market Research Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Peripheral Intravenous Catheter Market: Asia Pacific Regional Market to Witness the Fastest Growth Throughout the Forecast Period: Global Industry Analysis & Opportunity Assessment, 2016-2021
Peripheral intravenous catheter is a sophisticated medical device widely used to deliver certain flu...
27 Dec 2017 by Future Market Insights USD $5,000 More Info
Global Medical Intravenous Infusion Pump Market Research Report Forecast 2017 to 2021
The Global Medical Intravenous Infusion Pump Market Research Report Forecast 2017-2021 is a valuable...
28 Apr 2017 by S&P Consulting USD $2,800 More Info
Global Intravenous Needles Market Research Report Forecast 2017 to 2021
The Global Intravenous Needles Market Research Report Forecast 2017-2021 is a valuable source of ins...
28 Apr 2017 by S&P Consulting USD $2,800 More Info
Global Intravenous (IV) Iron Drugs Market Research Report Forecast 2017 to 2021
The Global Intravenous (IV) Iron Drugs Market Research Report Forecast 2017-2021 is a valuable sourc...
27 Apr 2017 by S&P Consulting USD $2,800 More Info
Global Intravenous Immunoglobulin (IVIg) Market Research Report Forecast 2017 to 2022
Delivery of the Report will take 2-3 working days once order is placed.The Global Intravenous Immuno...
26 Apr 2017 by S&P Consulting USD $2,800 More Info
Global Intravenous Fluid Containers Market Research Report Forecast 2017 to 2021
The Global Intravenous Fluid Containers Market Research Report Forecast 2017-2021 is a valuable sour...
26 Apr 2017 by S&P Consulting USD $2,800 More Info
Global Intravenous Immunoglobulin (IVIg) Market Research Report Forecast 2017 to 2021
The Global Intravenous Immunoglobulin (IVIg) Market Research Report Forecast 2017-2021 is a valuabl...
25 Apr 2017 by S&P Consulting USD $2,800 More Info
Global Disposable Intravenous Catheter Market Research Report Forecast 2017 to 2021
The Global Disposable Intravenous Catheter Market Research Report Forecast 2017-2021 is a valuable s...
25 Apr 2017 by S&P Consulting USD $2,800 More Info
Intravenous Solutions
Intravenous Solutions Market research report is analyzed by Type and Nutrients for each of the geogr...
01 Apr 2016 by Research Impact USD $4,500 More Info
U.S. General Anesthesia Drugs Market by Molecule (Propofol, Benzodiazepines, ketamine(s(+) ketamine HCl), Methohexital Sodium), route of administration (Intravenous, Inhalational), Supply Chain (GPOs, Distributors), Competitive - Analysis Forecast to 2020
The report segments the U.S. general anesthesia drugs market on the basis of molecule and route of a...
24 Jul 2015 by MarketsandMarkets USD $5,650 More Info

This report is published by Allied Market Research

Download Free Report Summary PDF

Global Intravenous Immunoglobulin Market (By Application, Types and Geography) - Size, Share, Global Trends, Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2014 - 2021 [Report Updated: 01-12-2016] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • 360i Research
  • 99Strategy
  • Allied Market Research
  • Asia Market Information & Development Co.
  • Azoth Analytics
  • BioInformant
  • Bizwit Research and Consulting
  • Black Swan Analysis
  • Canadean
  • CBR Pharma Insights
  • CRI
  • Current Analysis
  • Current Partnering
  • Daedal Research
  • Data bridge
  • Delve Insight
  • DPI Research
  • FirstWord Pharma
  • Future Market Insights
  • GBI Research
  • Global Data
  • Global Markets Direct
  • Global Research and Data Services GRDS
  • GMR Data
  • HeyReport
  • HongChun
  • HTStec
  • ICD Research
  • iGATE Research
  • IMARC
  • Industry ARC
  • Inkwood Research
  • IQ4I
  • Jain PharmaBiotech
  • Kelly Scientific
  • La Merie
  • Lifescience Intellipedia
  • LP Information
  • Market Data Forecast
  • Market Research Future
  • Marketline
  • MarketsandMarkets
  • McDerson
  • MedMarket Diligence
  • Meticulous Research
  • MicroMarketMonitor
  • MIReports
  • Mordor Intelligence LLC
  • MP Advisors
  • Occams Business Research
  • Prof Research
  • Progressive Markets
  • ProGrow Pharma Partners
  • Renub
  • Research Impact
  • RNCOS
  • Rockville Research
  • S&P Consulting
  • StratisticsMRC
  • The Business Research Company
  • Triton Market Research
  • Venture Planning Group (VPG)
  • VPA Research